Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nirdosh Kumar

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
International Journal of Radiation Oncology, Biology, Physics|February 21, 2012
Split-course, high-dose palliative pelvic radiotherapy for locally progressive hormone-refractory prostate cancerNirdosh Kumar Gogna, Siddhartha Baxi, Brigid Hickey, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|October 3, 2013
GSTT1 null and MPO -463G>a polymorphisms and carboplatin toxicity in an Indian populationArundhati Bag, Nirdosh Kumar Pant, Lalit Mohan Jeena, et al.
Medical Hypotheses|June 12, 2020
A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2Swaroop Revannasiddaiah, Santhosh Kumar Devadas, Rasmi Palassery, et al.
Journal of Natural Science, Biology, and Medicine|December 11, 2012
Cancer patterns in Nainital and adjoining districts of Uttarakhand: A one year surveyArundhati Bag, Sarita Rawat, Nirdosh Kumar Pant, et al.
Indian Journal of Palliative Care|December 19, 2013
Palliative radiotherapy in locally advanced head and neck cancer after failure of induction chemotherapy: comparison of two fractionation schemesKailash Chandra Pandey, Swaroop Revannasiddaiah, Nirdosh Kumar Pant, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 3, 2006
Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology GroupNirdosh Kumar Gogna, John H L Matthews, Sandra L Turner, et al.
The Lancet. Oncology|November 16, 2012
Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trialJames W Denham, Chantelle Wilcox, David Joseph, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 7, 2012
Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancerJames W Denham, Chantelle Wilcox, David S Lamb, et al.
Journal of Medical Imaging and Radiation Oncology|June 4, 2021
Implementation of 3D conformal radiotherapy technology at the National Cancer Centre Mongolia: A successful Asia-Pacific collaborative initiativeEng-Siew Koh, Nirdosh Kumar Gogna, Minjmaa Minjgee, et al.
The Lancet. Oncology|December 24, 2018
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trialJames W Denham, David Joseph, David S Lamb, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
International Journal of Radiation Oncology, Biology, Physics|February 21, 2012
Split-course, high-dose palliative pelvic radiotherapy for locally progressive hormone-refractory prostate cancerNirdosh Kumar Gogna, Siddhartha Baxi, Brigid Hickey, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|October 3, 2013
GSTT1 null and MPO -463G>a polymorphisms and carboplatin toxicity in an Indian populationArundhati Bag, Nirdosh Kumar Pant, Lalit Mohan Jeena, et al.
Medical Hypotheses|June 12, 2020
A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2Swaroop Revannasiddaiah, Santhosh Kumar Devadas, Rasmi Palassery, et al.
Journal of Natural Science, Biology, and Medicine|December 11, 2012
Cancer patterns in Nainital and adjoining districts of Uttarakhand: A one year surveyArundhati Bag, Sarita Rawat, Nirdosh Kumar Pant, et al.
Indian Journal of Palliative Care|December 19, 2013
Palliative radiotherapy in locally advanced head and neck cancer after failure of induction chemotherapy: comparison of two fractionation schemesKailash Chandra Pandey, Swaroop Revannasiddaiah, Nirdosh Kumar Pant, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 3, 2006
Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology GroupNirdosh Kumar Gogna, John H L Matthews, Sandra L Turner, et al.
The Lancet. Oncology|November 16, 2012
Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trialJames W Denham, Chantelle Wilcox, David Joseph, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 7, 2012
Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancerJames W Denham, Chantelle Wilcox, David S Lamb, et al.
Journal of Medical Imaging and Radiation Oncology|June 4, 2021
Implementation of 3D conformal radiotherapy technology at the National Cancer Centre Mongolia: A successful Asia-Pacific collaborative initiativeEng-Siew Koh, Nirdosh Kumar Gogna, Minjmaa Minjgee, et al.
The Lancet. Oncology|December 24, 2018
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trialJames W Denham, David Joseph, David S Lamb, et al.
Pageof 3